logo

GERON CORP(NSDQ:GERN)
Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.
# Employees: 103
Address: 230 Constitution Drive,Menlo Park,CA,USA
Phone: 650 473-7700
Fax: 650-473-7750
Website: www.geron.com
Email: info@geron.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
Thomas B. Okarma Ph.D. (Presi.; C.E.O.; Dir.)
David J. Earp (Sr. V.P.; Business Devlp. & Chief Patent Counsl.)
Melissa A. Kelly Behrs (Sr. V.P.; Therapeutic Develp.; Oncology)
Jane S. Lebkowski Ph.D. (Sr. V.P.; Regenerative Medicine)
David L. Greenwood (Exec. V.P.; C.F.O.; Treas. & Sec.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 2/25/2010
Mean EPS (Next Qtr): ($0.17)
Mean EPS (Year): ($0.76)
Mean Estimate(Long Term): $5.00
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 5
Shares Performance
Period GERN Compare to S&P
YTD 19.49 % -1.11 %
4 Weeks -13.08 % -14.02 %
12 Weeks -22.28 % -26.73 %
Shares Information
Analyst Coverage: Y
Avg Volume: 1577778
Shares Outstanding: 91M
Market Cap: $0.51B
52 Week High: $9.17
52 Week Low: $2.85
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 1/1/1990 GERN split by factor of 0.020
Earnings Performance
EPS Growth in Last Quarter: 26.09 %
EPS Growth in Last Year: 22.73 %
Sales Growth in Last Quarter: 169.95 %
Sales Growth in Last Quarter: 34.60 %
Financials
Qtr Book Value: $2.78
Cash Flow/Share: ($0.01)
Change in Payout Ratio: -0.010
Price/Sales: 305.160
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia